Last week, GenomeWeb's readers were most interested in a lawsuit filed against Illumina, Thermo Fisher, and others, alleging trade secrets theft and fraud.
Lucence's test are designed to detect DNA fragments shed by a tumor into the blood and target the most common cancers in Asia such as lung cancer.
The researchers distinguished histologic subtypes of appendiceal cancer and confirmed that it is distinct from colorectal and other GI cancers.
With genotyping data for more than 100,000 endometrial cancer cases and controls, researchers found nine new risk loci before delving into genes and pathways involved.
The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.
Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.
The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.
The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.
National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.
In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.